These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37111743)

  • 1. Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations.
    Osipova N; Budko A; Maksimenko O; Shipulo E; Vanchugova L; Chen W; Gelperina S; Wacker MG
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
    Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
    Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.
    Li M; Panagi Z; Avgoustakis K; Reineke J
    Int J Nanomedicine; 2012; 7():1345-56. PubMed ID: 22419876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
    Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
    J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
    Aishwarya R; Murthy A; Ahmed T; Chachad S
    J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
    Matteelli A; Villani P; Carvalho AC; El-Hamad I; Cusato M; Apostoli A; Marcantoni C; Calabresi A; Dal Zoppo S; Bigoni S; Regazzi M
    J Antimicrob Chemother; 2012 Oct; 67(10):2470-3. PubMed ID: 22678727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy.
    Ranjan AP; Mukerjee A; Helson L; Vishwanatha JK
    J Nanobiotechnology; 2012 Aug; 10():38. PubMed ID: 22937885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients.
    Sahai J; Narang PK; Hawley-Foss N; Li RC; Kamal M; Cameron DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):274-9. PubMed ID: 7788425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Biopharmaceutical Performance of Supersaturating Formulations of Carbamazepine in Rats Using Physiologically Based Pharmacokinetic Modeling.
    Thakore SD; Thakur PS; Shete G; Gangwal R; Narang AS; Sangamwar AT; Bansal AK
    AAPS PharmSciTech; 2019 Apr; 20(5):179. PubMed ID: 31041552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach.
    Chen F; Liu H; Wang B; Yang Z; Chen Y; Yang L; Wang B; Jiao Z; Lin HS; Quan Y; Wang H; Xiang X
    AAPS PharmSciTech; 2020 Aug; 21(7):245. PubMed ID: 32856178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Nanocarrier-Mediated Drug Delivery System to Enhance the Oral Bioavailability of Rifabutin.
    Nirbhavane P; Vemuri N; Kumar N; Khuller GK
    AAPS PharmSciTech; 2017 Apr; 18(3):829-837. PubMed ID: 27350276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.
    Verma RK; Kaur J; Kumar K; Yadav AB; Misra A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3195-201. PubMed ID: 18591268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
    Rafiei P; Haddadi A
    Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.